Eric J. Delgado

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

Cooley advised the initial purchaser of GameStop in connection with GameStop’s offering of $2.25 billion aggregate principal amount of 0.00% convertible senior notes due 2032.

Cooley advised Bicycle Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of medicines referred to as Bicycle molecules, on its $555.5 million private placement offering. Partners Laura Berezin, Jaime Chase and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.